Millions of people are now being treated with incretin agonism-based anti-obesity medications, making it a global priority to fully understand their action mechanisms and systemic effects and further enhance their safety and efficacy. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.